<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02768870</url>
  </required_header>
  <id_info>
    <org_study_id>HMCE-1002j</org_study_id>
    <nct_id>NCT02768870</nct_id>
  </id_info>
  <brief_title>CE Mark Study for the Harpoon Medical Device</brief_title>
  <acronym>TRACER</acronym>
  <official_title>Mitral TRans-Apical neoChordal Echo-guided Repair (TRACER) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and performance of the Harpoon Medical
      device. It is anticipated, that the Harpoon Medical device will provide advantages over
      current surgical interventions including: 1) a small minimally invasive incision, 2) no
      sternotomy, 3) no cardiopulmonary bypass, 4) no aortic manipulation, 5) a direct path to the
      valve plane, 6) performed on a beating heart, 7) real-time TOE-guided chordal length
      adjustment and 8) less complicated procedure that is teachable and adoptable.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The device is designed to reduce the degree of mitral regurgitation by delivering and
      anchoring artificial chordae tendineae to the affected mitral valve leaflet(s) in a beating
      heart.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject's Procedural Success During the First 30 Days</measure>
    <time_frame>Procedure and 30 days</time_frame>
    <description>Procedural success was defined as the patient leaving the operating room with a successful implant of one or more ePTFE cords on the mitral valve and reduced mitral regurgitation from severe to &lt;/=moderate at the conclusion of the procedure and at 30 days post-procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subject's With Freedom From Serious Adverse Events (SAE) &lt;/= 30 Days</measure>
    <time_frame>Procedure and 30 days</time_frame>
    <description>Subject's freedom from Serious Adverse Events during the ePTFE implantation procedure and at 30 days follow-up. Time to events were estimated by Kaplan-Meier method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject's Serious Adverse Events (SAE) Through Discharge</measure>
    <time_frame>Discharge, an average of 5 days post implant</time_frame>
    <description>Number of Participants experiencing a Serious Adverse Event (SAE) through time of Discharge.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject's Severity of Mitral Regurgitation Over Time</measure>
    <time_frame>6 months, 12 months, 18 months, and 24 months</time_frame>
    <description>Valvular regurgitation occurs when the valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it. Valvular regurgitation is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 represents no regurgitation and 4 represents severe regurgitation. The numbers on the scale are reflected as follows: 0 = no leak, 1 = a trace leak, 2 = a mild leak, 3 = a moderate leak, and 4 = a severe leak.
Higher numbers on the scale show a worsening outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subject's With Freedom From Serious Adverse Events (SAE) Post-implant &gt; 30 Days</measure>
    <time_frame>6 months, 12 months, 18 months, and 24 months</time_frame>
    <description>Subject's freedom from Serious Adverse Events at &gt;30 days post-implant. Time to events were estimated by Kaplan-Meier method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Mitral Valve Regurgitation</condition>
  <condition>Mitral Valve Prolapse</condition>
  <condition>Mitral Valve Insufficiency</condition>
  <arm_group>
    <arm_group_label>Harpoon Medical Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a prospective, single arm, nonrandomised, multi-center EU study to demonstrate the performance and safety of the Harpoon Medical device in patients with degenerative MR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Harpoon Artificial ePTFE Chords</intervention_name>
    <description>It is anticipated that use of the Harpoon device could achieve similar outcomes to open cardiac surgery while decreasing the invasiveness of mitral valve repair.</description>
    <arm_group_label>Harpoon Medical Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Patient referred for mitral valve surgery

          -  Presence of severe MR as read on an echocardiographic study performed within 60 days
             prior to procedure

          -  Estimated post-ePTFE chordae tendineae implantation coaptation surface is adequate in
             the judgment of the operating surgeon and the patient eligibility committee

          -  Degenerative mitral valve disease

          -  Patient is able to sign informed consent and able to return for follow-up and is
             capable of participating in all testing associated with this clinical investigation

          -  Women of child-bearing potential have a negative pregnancy test

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Infective endocarditis

          -  Anterior or bileaflet prolapse

          -  Functional MR

          -  History of Mediastinal Radiation

          -  Inflammatory (rheumatic) valve disease

          -  Requirement for concomitant cardiac surgery (e.g., coronary artery bypass grafting
             (CABG), aortic valve surgery, etc.)

          -  Symptomatic coronary artery disease

          -  Cardiogenic shock at the time of enrollment

          -  ST segment elevation myocardial infarction requiring intervention within 30 days prior
             to enrollment

          -  Evidence of cirrhosis or hepatic synthetic failure

          -  Pregnancy at the time of enrollment (women of child bearing age should have negative
             pregnancy within 14 days of surgery)

          -  Severe pulmonary hypertension (PA systolic pressure &gt; 70 mmHg)

          -  Previous cardiac surgery, or surgery on the left pleural space

          -  Left ventricular, atrial or appendage thrombus

          -  Severely calcified mitral leaflets

          -  Recent stroke (&lt; 6 months) with permanent impairment

          -  EuroScore (for mitral valve repair) &gt; 8%

          -  Patients with contraindications to Transoesophageal echocardiography

          -  Severe left or right ventricular dysfunction

          -  NYHA Class IV

          -  Renal insufficiency CKD stage 3b or worse (GFR &lt; 45 ml/min/1.73 m2)

          -  Patient is participating in another clinical study for which follow-up is currently
             ongoing. (Co-enrollment in an investigational device or interventional study)

          -  Patient with non-cardiac co-morbidities and life expectancy &lt; 1 year

          -  Patient has a condition or conditions that, in the opinion of the Investigator,
             preclude participation, including willingness to comply with all follow-up procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gino Gerosa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Padova</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ottavio Alfieri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OSR San Raffaele Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alison Duncan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Royal Brompton Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale San Raffaele Hospital</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Padova</name>
      <address>
        <city>Padova</city>
        <zip>351278</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Brompton and Harefield NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SH3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Trust</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Gammie JS, Bartus K, Gackowski A, D'Ambra MN, Szymanski P, Bilewska A, Kusmierczyk M, Kapelak B, Rzucidlo-Resil J, Moat N, Duncan A, Yadev R, Livesey S, Diprose P, Gerosa G, D'Onofrio A, Pitterello D, Denti P, La Canna G, De Bonis M, Alfieri O, Hung J, Kolsut P. Beating-Heart Mitral Valve Repair Using a Novel ePTFE Cordal Implantation Device: A Prospective Trial. J Am Coll Cardiol. 2018 Jan 2;71(1):25-36. doi: 10.1016/j.jacc.2017.10.062. Epub 2017 Nov 1.</citation>
    <PMID>29102688</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>April 20, 2016</study_first_submitted>
  <study_first_submitted_qc>May 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2016</study_first_posted>
  <results_first_submitted>September 23, 2019</results_first_submitted>
  <results_first_submitted_qc>November 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 25, 2019</results_first_posted>
  <last_update_submitted>November 5, 2019</last_update_submitted>
  <last_update_submitted_qc>November 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mitral Valve Repair</keyword>
  <keyword>Transapical</keyword>
  <keyword>Artificial Chordae</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
    <mesh_term>Mitral Valve Prolapse</mesh_term>
    <mesh_term>Prolapse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT02768870/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Harpoon Medical Device</title>
          <description>Safety and Performance study of the Harpoon Medical Device in subjects with degenerative mitral regurgitation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Implanted With Device</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not Implanted with Device</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reoperation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>On Study</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects who received the Harpoon Medical Device.</population>
      <group_list>
        <group group_id="B1">
          <title>Harpoon Medical Device</title>
          <description>Safety and Performance study of the Harpoon Medical Device in subjects with degenerative mitral regurgitation.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.5" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subject's Procedural Success During the First 30 Days</title>
        <description>Procedural success was defined as the patient leaving the operating room with a successful implant of one or more ePTFE cords on the mitral valve and reduced mitral regurgitation from severe to &lt;/=moderate at the conclusion of the procedure and at 30 days post-procedure.</description>
        <time_frame>Procedure and 30 days</time_frame>
        <population>This outcome is reported for enrolled subjects where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Harpoon Medical Device</title>
            <description>Safety and Performance study of the Harpoon Medical Device in subjects with degenerative mitral regurgitation.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Procedural Success During the First 30 Days</title>
          <description>Procedural success was defined as the patient leaving the operating room with a successful implant of one or more ePTFE cords on the mitral valve and reduced mitral regurgitation from severe to &lt;/=moderate at the conclusion of the procedure and at 30 days post-procedure.</description>
          <population>This outcome is reported for enrolled subjects where data is available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subject's With Freedom From Serious Adverse Events (SAE) &lt;/= 30 Days</title>
        <description>Subject's freedom from Serious Adverse Events during the ePTFE implantation procedure and at 30 days follow-up. Time to events were estimated by Kaplan-Meier method.</description>
        <time_frame>Procedure and 30 days</time_frame>
        <population>This outcome is reported for subjects who received the Harpoon Medical Device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Harpoon Medical Device</title>
            <description>Safety and Performance study of the Harpoon Medical Device in subjects with degenerative mitral regurgitation.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subject's With Freedom From Serious Adverse Events (SAE) &lt;/= 30 Days</title>
          <description>Subject's freedom from Serious Adverse Events during the ePTFE implantation procedure and at 30 days follow-up. Time to events were estimated by Kaplan-Meier method.</description>
          <population>This outcome is reported for subjects who received the Harpoon Medical Device where data is available.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>KM estimate: Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KM estimate: 30 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subject's Serious Adverse Events (SAE) Through Discharge</title>
        <description>Number of Participants experiencing a Serious Adverse Event (SAE) through time of Discharge.</description>
        <time_frame>Discharge, an average of 5 days post implant</time_frame>
        <population>This outcome is reported for subjects who received the Harpoon Medical Device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Harpoon Medical Device</title>
            <description>Safety and Performance study of the Harpoon Medical Device in subjects with degenerative mitral regurgitation.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Serious Adverse Events (SAE) Through Discharge</title>
          <description>Number of Participants experiencing a Serious Adverse Event (SAE) through time of Discharge.</description>
          <population>This outcome is reported for subjects who received the Harpoon Medical Device where data is available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject's Severity of Mitral Regurgitation Over Time</title>
        <description>Valvular regurgitation occurs when the valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it. Valvular regurgitation is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 represents no regurgitation and 4 represents severe regurgitation. The numbers on the scale are reflected as follows: 0 = no leak, 1 = a trace leak, 2 = a mild leak, 3 = a moderate leak, and 4 = a severe leak.
Higher numbers on the scale show a worsening outcome.</description>
        <time_frame>6 months, 12 months, 18 months, and 24 months</time_frame>
        <population>This outcome is reported for subjects who received the Harpoon Medical Device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Harpoon Medical Device</title>
            <description>Safety and Performance study of the Harpoon Medical Device in subjects with degenerative mitral regurgitation.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Severity of Mitral Regurgitation Over Time</title>
          <description>Valvular regurgitation occurs when the valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it. Valvular regurgitation is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 represents no regurgitation and 4 represents severe regurgitation. The numbers on the scale are reflected as follows: 0 = no leak, 1 = a trace leak, 2 = a mild leak, 3 = a moderate leak, and 4 = a severe leak.
Higher numbers on the scale show a worsening outcome.</description>
          <population>This outcome is reported for subjects who received the Harpoon Medical Device where data is available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 month follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 month follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 month follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 month follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subject's With Freedom From Serious Adverse Events (SAE) Post-implant &gt; 30 Days</title>
        <description>Subject's freedom from Serious Adverse Events at &gt;30 days post-implant. Time to events were estimated by Kaplan-Meier method.</description>
        <time_frame>6 months, 12 months, 18 months, and 24 months</time_frame>
        <population>This outcome is reported for subjects who received the Harpoon Medical Device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Harpoon Medical Device</title>
            <description>Safety and Performance study of the Harpoon Medical Device in subjects with degenerative mitral regurgitation.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subject's With Freedom From Serious Adverse Events (SAE) Post-implant &gt; 30 Days</title>
          <description>Subject's freedom from Serious Adverse Events at &gt;30 days post-implant. Time to events were estimated by Kaplan-Meier method.</description>
          <population>This outcome is reported for subjects who received the Harpoon Medical Device where data is available.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>KM estimate: 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KM estimate:12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KM estimate:18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KM estimate:24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Events occurring from baseline through 24 months post implant.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Harpoon Medical Device</title>
          <description>Safety and Performance study of the Harpoon Medical Device in subjects with degenerative mitral regurgitation.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia - Persistent atrial fibrillation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cardiovascular - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Regurgitation - Mitral-indeterminate +4</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nonspecific, unknown, or other body system - Other complication</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>ePTFE cordal rupture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>ePTFE knot pull-out/detachment (from leaflet)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion - Left</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia - AV block - 1st degree</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Regurgitation - Mitral-indeterminate +2</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Arrhythmia - AV block - 3rd degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Bundle branch block - Left</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Paroxysmal Atrial Fibrillation (PAF)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Regurgitation - Mitral-indeterminate +1</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nonspecific, unknown, or other body system - Other complication</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Metabolic complications</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sternal wound/Thoracic infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Wound infection – Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary – Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection (UTI)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion - Left</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Respiratory failure - Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Respiratory infection – Upper (URI)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI shall not publish site data until first multi-center publication. Publications will be submitted to Sponsor for review 60 days prior to publication/dissemination. Sponsor may ask for a 6-month delay of publication to protect proprietary information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrey Nersesov, Sr. Director of Clinical Affairs, Surgical Structural Heart</name_or_title>
      <organization>Edwards Lifesciences, LLC</organization>
      <phone>949-250-2500 ext 0225</phone>
      <email>Andrey_Nersesov@edwards.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

